ArticleImmunology2002
Necessity of the stalk region for immunoglobulin E interaction with CD23.
Article in Immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 22 citations in OpenAlex.
- IgE binds asymmetrically to its B cell receptor CD23.Scientific reports · 2017Article
- Critical and direct involvement of the CD23 stalk region in IgE binding.The Journal of allergy and clinical immunology · 2017Article
- Antigen transfer from exosomes to dendritic cells as an explanation for the immune enhancement seen by IgE immune complexes.PloS one · 2014Article
- Ca2+-dependent structural changes in the B-cell receptor CD23 increase its affinity for human immunoglobulin E.The Journal of biological chemistry · 2013Article
- The role of allergy in the etiopathogenesis of idiopathic sudden sensorineural hearing loss.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2013Article
- Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- CD23 Sheddase A disintegrin and metalloproteinase 10 (ADAM10) is also required for CD23 sorting into B cell-derived exosomes.The Journal of biological chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Previously, a soluble mouse CD23 chimera, composed of an N-terminal trimeric isoleucine zipper motif (lz) followed by the entire extracellular region (amino acids 48-331) of CD23 (lz-CD2348-331), was prepared and exhibited strong binding to rodent immunoglobulin E (IgE). In the current study, we report the construction of a similar human chimeric protein (lz-huCD2345-321), as well as a series of murine chimeric lz-CD23 mutants with incremental portions of stalk deleted, to further investigate the role of the stalk region in mediating the CD23-IgE interaction. All chimeric proteins were designed such that the predicted heptad structure of the stalk was retained. IgE binding, as determined by the capacity to inhibit 125I-IgE from binding to FcepsilonRI-bearing RBL-2H3 cells, and by surface plasmon-resonance analysis using an IgE-coated sensor chip, was unchanged from the original lz chimera and the binding parameters were similar to those of cell-surface CD23. The minimal murine chimera that retained IgE-binding activity was lz-CD23139-331, which still contains 35 amino acids of the stalk region. When the lz motif was linked to CD23 amino acid 157 (or higher), significant IgE-binding capacity was lost. With human lz-CD23, as with mouse, deletion of the stalk greatly reduced IgE-binding ability. In summary, the data support the concept that at least a portion of the stalk region of CD23 plays a crucial role in maintaining high-affinity/avidity interaction with IgE. The lz-CD23 constructs represent a possible alternative for both blocking the IgE/FcepsilonRI interaction and inhibiting IgE production by B lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.